Type Size

    Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized Controlled Trial.

    These authors examined the dose response curve (1, 2.5 or 5 mg given once) in patients with osteopenia for the ability of zolendronate to increase bone mineral density and alter bone turnover markers over one year.  They found evidence of a dose response effect on bone turnover markers while increases in bone mass were similar for all doses of zolendronate.  The authors conclude that annual administration of zolendronate at doses lower than 5 mg produced substantial antiresorptive effects and trials assessing the antifracture efficacy of low doses of zolendronate are justified. 


    Grey A, Bolland M, Wong S, Horne A, Gamble G, Reid IR.